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Summary
We performed a systematic review of the literature to establish whether revascularisation of the left subclavian territory is necessary when this
artery is covered by a stent. We retrieved data from 99 studies incorporating 4906 patients. Incidences of left-arm ischaemia (0.0% vs 9.2%,
p = 0.002) and stroke (4.7% vs 7.2%, p < 0.001) were significantly less following revascularisation, although mortality (10.5% vs 3.4%, p = 0.032)
and endoleak incidence (25.8% vs 12.6%, p = 0.008) were increased. No significant differences in spinal-cord ischaemia were seen. Revascular-
isation may reduce downstream ischaemic complications but can cause significant risk. Indications must be carefully considered on an individual
patient basis.
# 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Thoracic aortic pathology has traditionally been treated
by open surgery. The development of thoracic endovascular
aortic repair (TEVAR) has introduced an attractive alter-
native with reported reduced morbidity and perioperative
mortality [1]. Advantages such as negating the need for
thoracotomy and aortic cross-clamping must be tempered by
consideration of the complications. Management and,
especially, stenting of the aortic arch present a specific
challenge in view of the head-and-neck vessel origins
because a key factor in the successful deployment of a stent
is the provision of a suitable proximal landing zone (LZ),
which should be at least 15—20 mm [2,3].
Endovascular management in the vicinity of the left
subclavian artery (LSA) origin may necessitate incursion of
that boundary to create an adequate LZ. Stents have,
therefore, been deployed partially or completely across the§ We are grateful for the support from the NIHR Biomedical Research Centre
Funding Scheme.
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the left arm but also the origin of three important branches:
the left internal mammary artery (LIMA), the vertebral artery
and the costocervical trunk. The LIMA is the preferred donor
conduit for coronary artery bypassing. The vertebral artery
supplies the posterior part of the circle of Willis with the
basilar artery and also contributes to spinal-cord perfusion
via the anterior spinal and posterior spinal arteries. The
costocervical trunk can also contribute to spinal-cord
perfusion [3].
As a result, LSA coverage has been associated with
downstream ischaemic complications such as left-arm
ischaemia, spinal-cord ischaemia and stroke [2—4]. Myocar-
dial ischaemia in patients with LIMA to coronary artery bypass
graft (CABG) has also been reported. However, coverage of
the LSA origin has also been shown to be complication-free
with no downstream ischaemic consequences [3].
To prevent or to treat coverage complications, it is
possible to revascularise the LSA territory, before or after
TEVAR, respectively, usually by LSA to left-carotid-artery
bypass or transposition [5]. The revascularisation itself is
associated with mortality and morbidity such as nerve injury,
graft infection, lymphatic leakage and stroke [6].
The optimal management of the LSA in the context of
TEVAR, therefore, remains unclear and guidelines do not exist,
especially with regard to the revascularisation requirement.Surgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Search strategy and outcome.Different practice strategies exist with some centres elec-
tively covering the LSA in isolationwithout performing surgical
revascularisation [3]. This may be appropriate in some but not
all patients because complications occur. Specific indications
where collateral prior revascularisation must be performed
are recognised. Examples include patients with previous LIMA
conduits for CABG, left-handed professionals, dialysis patients
with left-arm arteriole-venous shunts, patients with anato-
mical variations such as a common origin of the LSA and left
common carotid artery and those with vertebral or carotid
artery stenosis [7]. Inaddition,direct involvementof theLSA in
the underlying aortic pathology, such as aneurysmal disease,
may oblige pre-emptive revascularisation. Other centres
perform revascularisation if deemed necessary as a second
step on a ‘wait-and-see’ basis in response to ensuing coverage
complications such as signs of ischaemia or malperfusion.
The question remains as to who should receive which
treatment and when. Recent studies addressing this con-
troversy have been published though this study represents
the largest quantitative and comprehensive approach to date
[2,4,8].
1.1. Study aims
Aims were to establish the evolution of clinical practice
regarding LSA coverage and revascularisation and to compare
outcomes in patients with LSA coverage with and without LSA
revascularisation. We also aimed to identify the complica-
tions of LSA revascularisation and their incidence. Our final
goal was to try to develop an evidence-based approach to
management of the LSA during thoracic-aortic stenting.
2. Material and methods
2.1. Literature search
An extensive multilayer literature search using a broad
comprehensive searching protocol was performed to ensure
capture of as many relevant studies as possible. First,
Medline, Ovid, Embase, Cochrane and the UK National Library
for Health databases were searched for all relevant studies
up to and including November 2008 using the following MeSH
search headings: ‘subclavian artery/blood supply’ OR ‘sub-
clavian artery/surgery’ AND ‘aorta, thoracic/surgery’ AND
‘complications’ OR ‘intraoperative complications’ OR ‘post-
operative complications’. Searches were also performed
using the terms: *Subclavian artery AND thorac* AND (stent*
OR graft* OR endovasc*). Abstracts of all articles resulting
from the search were reviewed. The search was then
broadened by reviewing abstracts of ‘related articles’.
Finally, the references of all recent review articles were
considered. In this way, we identified articles not brought to
our attention by the keyword search.
2.2. Study selection and data extraction
Two reviewers (Syed Rehman and Ryan Perera) indepen-
dently extracted the data from each study using a predefined
protocol. Studies were selected according to eligibility,
exclusion criteria and where primary outcomes, as definedbelow, were available. Data extracted included: first author,
year of publication, study population characteristics, study
design, number of LSA covered, number of LSA revascularised
before thoracic-aortic stenting, stenting indication, urgency,
complications in patients without LSA coverage, with LSA
coverage with and without pre-stenting LSA revascularisation
and complications due to LSA revascularisation.
Initially, all titles and abstracts (and full text where
abstracts were unavailable) were reviewed. All full texts
were then reviewed to generate the final study group (see
Fig. 1).
2.3. Eligibility criteria
We included all studies in which the LSA was covered by
thoracic-aortic stents for any aortic pathology. Further, all
studies in which the LSA (Zone 2) was covered with or without
revascularisation, which reported on primary or secondary
outcomes as defined below, were reported. (To facilitate LZ
selection, Ishimaru described a classification system where
each zone (Z0—Z4) is bordered by tangents aligned with the
distal sides of each orifice of the arteries branching off the
aortic arch.) [9].
2.4. Exclusion criteria
We excluded studies where the predefined primary or
secondary outcomes were not extractable, studies in which
thoracic-aortic-stent insertion was not radiologically guided
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studies with a patient population less than five and studies
not published in the English language. Where there was
overlap in data in studies reported by the same institution,
the analysis included either the better quality or more recent
publication and the ‘other’ study was excluded.
2.5. Primary outcomes
These included left-arm ischaemia (which was defined as
critical arm ischaemia and left-arm claudication symptoms
but not an asymptomatic reduction in blood pressure in the
left arm), stroke, spinal-cord ischaemia (which was defined
as paraplegia and paraparesis), endoleak (including all types
I—IV), stent migration and overall mortality.
2.6. Secondary outcomes — complications of LSA
revascularisation
Secondary outcomes were nerve injury (including Horner’s
syndrome, partial plexus palsy, phrenic nerve palsy and
recurrent laryngeal nerve palsy), lymphatic leak, post-
operative thrombosis, graft infection, haematoma and other.
2.7. Group comparison and sensitivity analysis
All study participants were classified into three defined
study groups (see Fig. 1) enabling comparison of outcomes:
group A who had with no LSA coverage, group B who
underwent LSA coverage without LSA revascularisation and
group C who underwent LSA coverage with LSA revascular-
isation.
Statistical analysis was performed on all studies for each
outcome comparing groups A, B and C (see Tables 2—4). There
were three stages of analysis. The first stage was to examine
the total incidence of a specific outcome between the two
groups. To examine this, we recorded the total incidence of
the complication for each group. We classified these as ‘all
studies’ and report the tabulated findings with the number of
studies shown where the incidence was reported. The secondTable 1. Studies selected with mean age, LSA management strategy and stenting in
Study Mean age LSA management
Covered Revascularised before st
Buth et al.a [15] 63.2 159 40
Thompson et al.a [13] 64 56 14
Feezor et al.a [16] 68.6 80 11
Farber and Criadoa [17] 66.5 9 0
Woo et al.a [18] 67 70 42
Morales et al.a [11] 71 66 0
Khoynezhad et al.a [19] 71 43 2
Schoder et al.a [20] 61.8 58 25
Melissano et al.a [21] 71 30 5
Peterson et al.a [5] 62 30 22
Morasch and Peterson [22] NS 28 21
Reece et al. [23] 60.4 27 7
Ferreira et al.a [24] NS 17 4
Appoo et al.a [25] 73.1 20 20
Steingruber et al.a [26] 38.7 20 0
Weigang et al.a [27] 64.3 20 1
Chung et al.a [28] 46 17 0stage was to refine this search further by selecting only those
studies where a direct comparison was made of the outcome
between the two groups. In this way, studies where the
incidence was reported in only one group were rejected. The
remaining studies were classified as ‘comparative studies’
and are tabulated with the respective number of studies and
subjects. The third stage of analysis was to perform a
subgroup analysis (sensitivity analysis) on studies published
before and after 2004 to determine if developments in
endovascular stenting in the last 5 years have impacted on
the selected outcomes. A subgroup analysis was also
performed to compare outcomes according to the underlying
aortic pathology (dissection, aneurysm and trauma) and
degree of clinical urgency.
Through performing this sensitivity analysis, an assess-
ment of the risk of bias was made at study level. This
approach not only enabled selection of only higher quality
studies, consequently reducing the risk of selection bias, but
also provided a mechanism for assessing the robustness of
results under different circumstances.
Statistical analysis was performed using the epidemiolo-
gical software Epi InfoTM Version 3.5.1 (Centres for Disease
Control and Prevention, Atlanta, GA, USA). Statistical
significance was achieved at p < 0.05. Statistical tests
performedwere chi-square with or without Yate’s correction.
3. Results
The initial MeSH term search generated 759 studies. A
further 1523 studies were identified from references and
related articles of the original search. Of these studies, 1982
studies were excluded. On expanding to full-text review, a
further 201 studies were excluded. This resulted in a final
study group of 99 publications, which constituted ‘all studies’
(see Fig. 1). From this, a variable number of studies (ns) were
excluded, generating groups of ‘comparative studies’ for
specific subgroup analysis. Demographic and clinical data are
presented in Table 1. In total, there were 4906 patients with
at least 1607, who were LSA covered.dication.
Stenting indication
enting AD AA AA rupture PAU IMH Trauma Other
215 317 0 0 0 67 7
67 88 0 3 1 21 0
34 103 0 32 0 9 18
11 0 11 0 0 0 0
16 44 5 0 0 4 1
52 116 0 0 0 10 8
67 91 0 14 0 12 0
20 29 3 2 0 4 0
2 24 0 2 0 2 0
5 45 0 0 6 14 0
NS NS NS NS NS NS NS
3 17 0 0 0 7 0
NS NS NS NS NS NS NS
0 99 0 0 0 0 0
0 0 0 0 0 22 0
10 9 1 0 0 0 0
0 0 0 0 0 26 0
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Table 1 (Continued )
Study Mean age LSA management Stenting indication
Covered Revascularised before stenting AD AA AA rupture PAU IMH Trauma Other
Scharrer-Pamler et al. [29] 69 15 1 0 34 11 0 0 0 0
Alsac et al.a [30] 45 13 0 0 0 0 0 0 28 0
Sunder-Plassmann et al. [31] 69 12 0 0 30 15 0 0 0 0
Czerny et al. [32] 72.3 11 11 3 8 0 0 0 0 0
Galili et al.a [33] NS 11 2 0 10 1 0 0 0 0
Melissano et al. [34] 71.4 10 0 0 21 0 0 0 0 0
Teisenhausen et al.a [35] NS 10 2 7 3 0 0 0 0 0
Buz et al. [36] 36 20 1 0 0 0 0 0 39 0
Pamler et al. [37] 60.3 9 0 14 0 0 0 0 0 0
Reisenman et al. [38] 70 9 0 4 35 7 2 0 2 0
Schumacher et al. [39] 65 25 25 2 23 NS 0 0 0 0
Bent et al. [40] 43.2 8 0 0 0 0 0 0 13 0
Orend et al. [41] NS 8 0 0 0 0 0 0 8 0
Schoder et al.a [42] 71.6 12 8 0 28 0 0 0 0 0
Schumacher et al. [43] 71 8 8 2 0 6 0 0 0 0
Hughes et al. [44] 63 13 0 1 12 0 0 0 0 0
Kutty et al. [45] 36 9 6 0 9 0 0 0 0 0
Lambrechts et al.a [46] 64 7 1 11 12 0 0 0 3 0
Matravers et al. [47] 71 7 NS 9 10 1 3 0 1 0
Pearce et al.a [48] 61 7 0 15 0 0 0 0 0 0
Rousseau et al. [49] 37 7 0 0 0 0 0 0 9 0
Tse et al.a [50] 73.2 7 5 6 18 2 0 8 3 0
Midulla et al.a [51] 47.6 6 3 0 8 0 0 0 0 0
Dagenais et al. [52] 63.3 6 0 2 11 0 6 0 4 1
Fattori et al.a [53] 39.4 6 0 0 0 0 0 0 19 0
Fu et al. [54] 47 6 4 9 1 0 0 0 0 0
Lawlor et al.a [55] 42.3 6 1 0 0 0 0 0 7 0
Neschis et al. [56] 40 6 0 0 0 0 0 0 20 0
Czerny et al. [57] 79.5 5 5 0 5 0 0 0 0 0
Destrieux-Garnier et al. [58] 62 5 0 17 5 0 5 0 5 0
Ferrari et al. [59] 40.7 4 0 0 0 0 0 0 18 0
Hausegger et al. [60] NS 5 1 5 0 0 0 0 0 0
McPhee et al.a [61] 30.8 4 0 0 0 0 0 0 8 0
Yamane et al. [62] 39 4 0 0 0 0 0 0 14 0
Bockler et al. [63] 66 4 2 7 17 4 0 0 0 0
Czermak et al. [64] 67 3 NS 7 0 0 0 0 0 0
Daenen et al.a [65] 46.9 3 1 0 0 0 0 0 7 0
Ianelli et al.a [66] 58.3 3 0 8 0 4 0 0 3 0
Inglese et al.a [67] 69.3 3 0 6 24 5 4 0 1 1
Amabile et al. [68] 32 2 0 0 0 0 0 0 9 0
Balzer et al.a [69] 61.3 6 0 8 9 7 0 0 2 0
Chan et al.a [70] 64.8 16 2 6 9 1 0 0 0 0
Czerny et al. [71] 63 NS 4 6 0 0 0 0 0 0
Kato et al.a [72] 56 2 0 0 0 0 0 0 10 0
Matsumura et al.a [73] 72 NS NS 0 137 0 23 0 0 0
Pitton et al. [74] 53.9 20 0 13 8 1 2 0 9 4
Saratzis et al. [75] 29.5 2 0 0 0 0 0 0 9 0
Teisenhausen et al. [76] 70 3 1 4 0 0 0 0 0 0
Brueck et al. [77] 62 NS 2 5 4 0 0 0 0 0
Fattori et al. [78] 40.6 8 2 0 0 0 0 0 51 0
Gonzalez-Fajardo et al. [79] 57 12 0 12 0 0 0 0 0 0
Grabenwoger et al. [80] 60 NS NS 11 0 0 6 0 2 0
Schoder et al.a [81] 70.6 2 0 0 0 0 8 0 0 0
Orend et al. [82] 34 NS NS 0 0 0 0 0 11 0
Neuhauser et al. [83] 39 8 0 0 0 0 0 0 13 0
Amabile et al. [84] 66 8 3 17 26 0 5 0 18 1
Apple et al.a [85] 72 8 6 1 21 0 2 0 3 0
Attia et al.a [86] 2 0 6 20 0 3 0 11 0
Bergeron et al. [87] 71.5 25 0 11 14 0 0 0 0 0
Bockler et al.a [88] 57 13 1 37 0 0 0 0 0 0
Botta et al.a [89] 71.8 1 1 0 0 0 19 0 0 0
Buffolo et al.a [90] 14 120 61 0 6 0 4 0
Czerny et al.a [71] 71.8 66 66 0 79 0 0 0 0 0
Di Tommaso et al.a [91] 63.5 10 0 26 18 0 0 0 7 0
Dick et al. [92] 68.8 13 0 37 9 0 0 0 0 6
Eggebrecht et al.a [93] 62.2 13 0 38 0 0 0 0 0 0
Go et al.a [94] 44 2 0 0 0 0 0 0 10 0
Go et al.a [95] 71 29 28 0 142 0 0 0 0 0
Gorich et al. [96] 51 23 0 9 3 11 0 0 0 0
Kokotsakis et al.a [97] 26.2 2 0 0 0 0 0 0 22 0
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Table 1 (Continued )
Study Mean age LSA management Stenting indication
Covered Revascularised before stenting AD AA AA rupture PAU IMH Trauma Other
Marcheix et al.a [98] 40 9 0 0 0 0 0 0 33 0
Marcheix et al.a [99] 68 6 0 0 45 0 0 0 0 0
Midgley et al.a [100] 43.8 8 0 0 0 0 0 0 12 0
Palma et al.a [101] 57.6 14 0 58 0 0 6 6 0 0
Patel et al.a [102] 67.4 16 3 0 0 0 0 0 0 0
Pauls et al.a [103] 74 4 0 0 0 0 12 0 0 0
Piffaretti et al.a [104] 17 1 13 14 0 12 0 8 0
Rodriguez et al. [105] 72 37 13 82 183 0 34 0 11 14
Sandroussi et al.a [106] 61.5 21 0 23 31 0 2 0 9 0
Schoder et al.a [107] 57 26 4 0 0 0 0 0 0 0
Xu et al.a [108] 50.4 16 0 63 0 0 0 0 0 0
Yang et al.a [109] 48.4 10 0 0 0 0 0 0 0 0
Total — 1561 438 1243 2139 96 213 21 674 61
LSA: left subclavian artery; AD: aortic dissection.; AA: aortic aneurysm; PAU: penetrating aortic ulcer; IMH: intramural haematoma; NS: not stated.
a Comparative study.The primary outcome findings of the comparison among
groups A, B and C are presented in Tables 2—4. These tables
demonstrate the results of subgroup analyses for the primary
outcomes utilising ‘all studies’, ‘comparative studies’ and
pre- and post-2004.
3.1. Group A versus group B — comparison of primary
outcomes between no LSA coverage and LSA coverage
without revascularisation (Table 2a and b)
Left-arm ischaemia was increased throughout all groups;
‘all studies’ ( p = 0.000), ‘comparative studies’ ( p < 0.001),
pre-2004 ( p = 0.008) and post-2004 ( p < 0.001). The inci-
dence of stroke was also greater in ‘all studies’ ( p = 0.076)
and post-2004 studies only ( p = 0.049). The incidence of
endoleak was increased in ‘all studies’ ( p = 0.066) and,
especially, pre-2004 ( p = 0.035).Table 2. (a) Comparison of primary outcomes between no LSA coverage and LSA cov
Outcome All studies
A(o) A(n) ns B(o) B(n) ns
Left-arm ischaemia 0 (0.0) 955 29 59 (9.2) 640 68
Stroke 68 (3.6) 1901 39 35 (5.1) 683 52
Spinal-cord ischaemia 35 (2.4) 1456 40 16 (3.0) 540 46
Endoleak 7 (6.1) 115 10 25 (12.6) 198 16
Stent migration 0 (0.0) 54 7 2 (1.8) 112 11
Mortality 1 (0.8) 129 10 7 (3.4) 207 20
Outcome Pre-2004
A(o) A(n) ns B(o) B(n) ns p
Left-arm ischaemia 0 (0.0) 132 8 7 (6.7) 104 17
Stroke 0 (0.0) 66 5 0 (0.0) 38 7 —
Spinal-cord ischaemia 2 (0.6) 316 10 1 (1.0) 99 12
Endoleak 1 (3.1) 32 3 11 (22.9) 48 6
Stent migration 0 (0.0) 45 4 1 (2.9) 35 6
Mortality 0 (0.0) 41 3 2 (4.4) 45 5
A(o): number (% incidence) of patients without LSA coverage who experienced outcom
of patients with LSA coverage without pre-stenting revascularisation who experience
revascularisation; ns: number of studies used in analysis.When covering the LSA without revascularisation, the
incidence of spinal-cord ischaemia was significantly reduced
in ‘comparative studies’ ( p = 0.017).
3.2. Group A versus group C — comparison of primary
outcomes between no LSA coverage and LSA coverage
with revascularisation (Table 3a and b)
In those undergoing coverage with revascularisation, the
incidence of stroke was elevated in analysing ‘all studies’
only ( p = 0.013). The incidence of endoleak was greater in
‘all studies’, ‘comparative studies’ ( p < 0.001 and p = 0.010,
respectively) and after 2004 ( p = 0.002). The incidence of
mortality was also increased ( p = 0.003) in ‘all studies’ when
revascularising the LSA.
There was no statistically significant difference in spinal-
cord ischaemia between the groups ( p = 0.51) though thereerage without revascularisation. (b) Subgroup analysis before and after 2004.
Comparative studies
p value A(o) A(n) B(o) B(n) ns p value
0.000 0 (0.0) 472 8 (4.8) 168 24 0.000
0.076 47 (3.3) 1434 20 (4.4) 458 33 0.27
0.48 14 (3.7) 378 21 (1.7) 1250 34 0.017
0.066 1 (2.5) 40 3 (5.6) 54 6 0.84
0.82 0 (0.0) 50 0 (0.0) 25 7 —
0.25 1 (0.8) 129 0 (0.0) 72 10 1.00
Post-2004
value A(o) A(n) ns B(o) B(n) ns p value
0.008 0 (0.0) 555 22 55 (10.3) 532 52 0.000
68 (3.9) 1731 34 36 (5.8) 618 44 0.049
1.00 33 (2.3) 1416 32 16 (3.3) 480 36 0.23
0.035 6 (7.2) 83 7 18 (10.9) 165 11 0.36
0.89 0 (0.0) 13 3 1 (1.3) 77 6 1.00
0.52 1 (1.1) 88 7 6 (3.2) 185 16 0.54
es listed; A(n): total patients without LSA coverage; B(o): number (% incidence)
d outcomes listed; B(n): total patients with LSA coverage without pre-stenting
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Table 3. (a) Comparison of primary outcomes between no LSA coverage and LSA coverage with revascularisation. (b) Subgroup analysis before and after 2004.
Outcome All studies Comparative studies
A(o) A(n) ns C(o) C(n) ns p value A(o) A(n) C(o) C(n) ns p value
Left-arm ischaemia 0 (0.0) 955 29 0 (0.0) 113 20 — 0 (0.0) 206 0 (0.0) 91 10 —
Stroke 68 (3.6) 1901 39 24 (7.1) 340 27 0.013 40 (3.5) 1149 12 (5.7) 210 18 0.12
Spinal-cord ischaemia 35 (2.4) 1456 40 3 (1.4) 213 21 0.51 16 (2.5) 643 1 (0.8) 125 12 0.40
Endoleak 7 (6.1) 115 10 24 (25.8) 93 11 0.000 1 (2.9) 35 3 (42.9) 7 3 0.010
Stent migration 0 (0.0) 54 7 0 (0.0) 37 5 — 0 (0.0) 5 0 (0.0) 2 2 —
Mortality 1 (0.8) 129 10 9 (10.5) 86 11 0.003 0 (0.0) 42 0 (0.0) 1 2 —
Outcome Pre-2004 Post-2004
A(o) A(n) ns C(o) C(n) ns p value A(o) A(n) ns C(o) C(n) ns p value
Left-arm ischaemia 0 (0.0) 132 8 0 (0.0) 18 5 — 0 (0.0) 555 22 0 (0.0) 95 15 —
Stroke 0 (0.0) 66 5 1 (5.9) 17 3 0.46 68 (3.9) 1731 34 19 (5.9) 323 24 0.11
Spinal-cord ischaemia 2 (0.6) 316 10 0 (0.0) 18 5 1.00 33 (2.3) 1416 32 3 (1.6) 184 16 0.74
Endoleak 1 (3.1) 32 3 1 (11.1) 9 2 0.92 6 (7.2) 83 7 23 (24.5) 94 9 0.002
Stent migration 0 (0.0) 45 4 0 (0.0) 9 2 — 0 (0.0) 13 3 0 (0.0) 28 3 —
Mortality 0 (0.0) 41 3 1 (12.5) 8 1 0.36 1 (1.1) 88 7 8 (10.3) 78 11 0.025
A(o): number (% incidence) of patients without LSA coverage who experienced outcomes listed; A(n): total patients without LSA coverage; C(o): number (% incidence)
of patients with LSA coverage with pre-stenting revascularisation who experienced outcomes listed; C(n): total patients with LSA coverage with pre-stenting
revascularisation; ns: number of studies used in analysis.was a relative reduction of 42% when performing LSA
revascularisation.
3.3. Group B versus group C — comparison of primary
outcomes between LSA coverage without and with
revascularisation, respectively (Table 4a and b)
When comparing LSA coverage with and without revascu-
larisation, significant differences were seen in the incidence
of left-arm ischaemia, which was reduced by revascularisa-
tion in ‘all studies’, ‘comparative studies’ and after 2004 (all
p values = 0.002). Stroke incidence was also relatively
reduced when analysing ‘comparative studies’ only
( p = 0.007).
However, revascularisation was also related to a sig-
nificant increase in the incidence of endoleak in ‘all studies’Table 4. (a) Comparison of primary outcomes between LSA coverage without and wit
Outcome All studies
B(o) B(n) ns C(o) C(n) ns
Left-arm ischaemia 59 (9.2) 640 68 0 (0.0) 113 20
Stroke 35 (5.1) 683 52 24 (7.1) 340 27
Spinal-cord ischaemia 16 (3.0) 540 46 3 (1.4) 213 21
Endoleak 25 (12.6) 198 16 24 (25.8) 93 11
Stent migration 2 (1.8) 112 11 0 (0.0) 37 5
Mortality 7 (3.4) 207 20 9 (10.5) 86 11
Outcome Pre-2004
B(o) B(n) ns C(o) C(n) ns p
Left-arm ischaemia 7 (6.7) 104 17 0 (0.0) 18 5 0
Stroke 0 (0.0) 38 7 1 (5.9) 17 3 0
Spinal-cord ischaemia 1 (1.0) 99 12 0 (0.0) 18 5 1
Endoleak 11 (22.9) 48 6 1 (11.1) 9 2 0
Stent migration 1 (2.9) 35 6 0 (0.0) 9 2 1
Mortality 2 (4.4) 45 5 1 (12.5) 8 1 0
B(o): number (% incidence) of patients with LSA coverage without pre-stenting reva
coverage without pre-stenting revascularisation; C(o): number (% incidence) of pat
outcomes listed; C(n): total patients with LSA coverage with pre-stenting revascula( p = 0.008) and after 2004 ( p = 0.004) and mortality in ‘all
studies’ ( p = 0.032) and post-2004 ( p = 0.021).
No significant differences in spinal-cord ischaemia
( p = 0.33) were seen though there was a relative reduction
of 53% when revascularising the LSA territory.
3.4. Secondary outcomes — complications of LSA
revascularisation
The secondary outcome findings of all studies that
reported LSA revascularisation complications are sum-
marised in Table 5. In total, this included 278 patients.
The overall complication rates were nerve injury 8.6%,
lymphatic leak 2.5%, postoperative thrombosis 1.1%, graft
infection 0.0%, haematoma 0.4%, haemorrhage 1.1%, wound
dehiscence 0.4%, stroke 0.7% and mortality 0.0%.h revascularisation respectively. (b) Subgroup analysis before and after 2004.
Comparative studies
p value B(o) B(n) C(o) C(n) ns p value
0.002 17 (10.2) 167 0 (0.0) 103 17 0.002
0.21 30 (7.2) 415 12 (4.7) 257 22 0.007
0.33 7 (3.4) 207 1 (0.8) 123 13 0.27
0.008 7 (10.3) 68 11 (31.4) 35 5 0.33
1.00 0 (0.0) 21 0 (0.0) 4 3 —
0.032 0 (0.0) 71 0 (0.0) 32 6 —
Post-2004
value B(o) B(n) ns C(o) C(n) ns p value
.56 55 (10.3) 532 52 0 (0.0) 95 15 0.002
.68 36 (5.8) 618 44 19 (5.9) 323 24 0.97
.00 16 (3.3) 480 36 3 (1.6) 184 16 0.36
.73 18 (10.9) 165 11 23 (24.5) 94 9 0.004
.00 1 (1.3) 77 6 0 (0.0) 28 3 1.00
.94 6 (3.2) 185 16 8 (10.3) 78 11 0.021
scularisation who experienced outcomes listed; B(n): total patients with LSA
ients with LSA coverage with pre-stenting revascularisation who experienced
risation; ns: number of studies used in analysis.
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Domenig et al.a [6] 150, 100 76:74 60.2, — 18 5 3 0 1 5
Woo et al. [18] 70, 63 53:17 67, — 1 0 0 0 0 0
Saleh [110] 16, 38 12:4 67, 45—82 0 1 0 0 0 0
Brueck et al. [77] 9, 22 5:4 62, 44—70 0 0 0 0 0 0
Czerny et al. [32] 11, 100 7:4 72.3, — 0 0 0 0 0 1
Peterson et al. [5] 70, 31 44:26 62, 22—85 2 0 0 0 0 0
Schoder et al. [20] 58, 47 45:13 61.8, 21—84 2 0 0 0 0 0
Cambria et al. [111] 28, 21 16:12 71, 36—91 0 0 0 0 0 0
Criado et al. [112] 47, 17 33:14 —, 33—88 0 1 0 0 0 0
Yano et al. [113] 50, 4 — —, — 1 0 0 0 0 0
M:F: male:female. Other complications in Domenig et al. [6] included two strokes and three haemorrhages and in Czerny et al. [32] included one wound dehiscence.
a Note: In this study only 26 out of the 150 patients underwent thoracic aortic endovascular stenting.
Table 6. Aortic pathology and outcome.
Outcome A(o) A(n) ns B(o) B(n) ns p value
Discussion
Left-arm ischaemia 0 (0.0) 161 22 4 (4.0) 101 14 0.043
Stroke 2 (1.4) 142 10 9 (9.0) 100 15 0.013
Endoleak 2 (4.0) 50 10 12 (29.3) 41 9 0.002
Aneurysm
Left-arm ischaemia 0 (0.0) 87 8 5 (8.6) 58 12 0.020
Please note that only statistically significant findings are shown. A(o): number (% incidence) of patients without LSA coverage who experienced outcomes listed; A(n):
total patients without LSA coverage; B(o): number (% incidence) of patients with LSA coverage without pre-stenting revascularisation who experienced outcomes
listed; B(n): total patients with LSA coverage without pre-stenting revascularisation; ns: number of studies used in analysis.3.5. Time-trend analysis in LSA coverage and
revascularisation
Chronological trends in LSA coverage with and without
revascularisation from 1997 to 2008 are demonstrated in
Fig. 2.
3.6. Underlying aortic pathology and outcome
Comparison of groups A, B and C according to three
different aetiologies (dissection, aneurysm and trauma)
demonstrated that in the case of dissection, the incidences
of left-arm ischaemia, stroke and endoleak were all
increased when covering the LSA in comparison to leaving
[(Fig._2)TD$FIG]
Fig. 2. Trends in LSA coverage and LSA revascularisation.the origin uncovered ( p = 0.043, 0.013 and 0.002, respec-
tively; see Table 6). The incidence of left-arm ischaemia was
also elevated in those with aneurysms when covering the LSA
origin ( p = 0.020). No other statistically significant findings
were demonstrated. Therefore, those with dissections (and
less so aneurysms) are more likely to develop LSA coverage
complications.
3.7. Clinical urgency
We assessed all studies to assess for a relationship
between clinical urgency and primary outcome. The only
statistically significant finding was for stroke where we found
that this outcome was more likely in elective patients than
emergencies (4.5% vs 0.7%, p = 0.004).
3.8. Types of endoleaks
We performed a subgroup analysis to compare the
incidence of different types (I and II) of endoleaks among
groups A, B and C. The results were similar as those for
endoleaks in general, except that the increase in incidence of
type I endoleaks in group C compared with group B was not
statistically significant ( p = 0.34).
4. Discussion
We established chronological trends in coverage and
revascularisation rates (Fig. 2) such that, initially, LSA
coverage was very high (1999) closely followed by a
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baseline until, in 2005, another revascularisation surge
was seen. By 2008, there were fairly equal coverage and
revascularisation incidences, suggesting a relative increase
in revascularisation uptake. This variation represents a lack
of consensus for optimal LSA management during TEVAR.
Potential influencing factors include varying surgical pre-
ferences and institution of guidelines (or, in this case, lack of
them).
The impact of LSA coverage without revascularisation, as
expected, demonstrated a significant increase in left-arm
ischaemia (9.2% vs 0.0%). This complication was obliterated
by revascularisation.
LSA coverage per se with or without revascularisation was
also found to increase the risk of stroke by 50% and 30% in
comparison to no LSA coverage. When revascularising, the
risk of stroke was relatively reduced by 30% with analysis of
‘comparative studies’ only demonstrating a statistically
significant reduction in the incidence of stroke.
The relative incidence of spinal-cord ischaemia was also
found to be reduced after revascularisation though this was
not statistically significant. There was a relative reduction
seen of 53% from 3.0% to 1.4%.
Important negative implications of revascularisation were
revealed in that the incidence of mortality and endoleak
were significantly increased. The rate of endoleak increased
from 13% to 26% (relative increase of 51%) when undergoing
LSA revascularisation. We expected to see a reduction in
stent migration in favour of LSA origin coverage in view of the
improved LZ; however, our results did not corroborate this.
This may be explained by the small number of patients
reported (35 vs 9 patients). Mortality, however, was
significantly different between the groups with a relative
increase of 68% when undergoing LSA revascularisation.
In addition, revascularisation was associated with further
independent complications. Nerve injuries were observed in
8.6% (24 out of 278 patients). However, 75% of these were
transient and resolved within 6 months of surgery [6]. The
rates of the other minor complications were all minimal.
We also demonstrated that in considering the underlying
aortic pathology where LSA coverage was required, those
with dissection (and, to a lesser extent, aneurysms) were
more likely to develop complications. We found no
statistically significant data to demonstrate that revascular-
isation was better or worse for differing aortic aetiologies.
Furthermore, the urgency influenced only the outcome of
stroke and the incidence of this complication was elevated in
the elective cases.
These conclusions provide the current available evidence
base to facilitate decision making in LSA management during
TEVAR. When it is necessary to cover the LSA origin to
facilitate the LZ, subsequent revascularisation reduces the
incidence of left-arm ischaemia and stroke. However, this
intervention may also be associated with an increase in the
rate of mortality, endoleak and morbidity. This precludes a
‘blanket statement’ approach to LSA management and
necessitates a thorough understanding of each clinical
scenario. We propose that proficient decision making in
LSA management requires a multifactorial thought process to
calculate an appropriate risk—benefit ratio, which may be
divided into patient, operator and hospital factors.4.1. Patient factors
This includes assessment of the individual’s specific
anatomy and consideration of the underlying pathology in
the context of its clinical urgency.
Anatomical assessment of the individual enables planning
the endovascular approach and mapping out the collateral
anatomy enabling prediction of downstream ischaemia.
Direct imaging of the aorta, and carotid and vertebral
arteries by ultrasound duplex, computed tomographic
angiography (CTA) and magnetic resonance angiography
(MRA) are available options [10,11]. Specific posterior
cerebral circulation layouts preclude the risk of stroke on
occluding the dominant artery and Feevor and Lee describe
that where they identified specific at-risk posterior circula-
tions and performed ‘expectant’ revascularisation, they
reduced their stroke rate from 6.4% to 2.3% [2].
In addition, LSA occlusion tests also enable prediction of
the consequences of LSA coverage. This involves performing
neurological tests while the LSA is temporarily occluded using
a balloon catheter to demonstrate potential complications
such as left arm, cerebellar, brain stem or spinal-cord
ischaemia [12]. Kurimoto et al. employed these tests to
demonstrate symptoms of vertebro-basilar insufficiency and
vertebral artery abnormalities in 6.5% and 6.7% of patients,
respectively. As a result, they performed revascularisation
surgery or fenestrated stent grafting in these patients to
preserve LSA perfusion and successfully prevent the occur-
rence of stroke [12]. In addition, the individual presentation
must be considered to ensure that there are no specific
influencing factors such as a previous LIMA harvest for CABG.
The underlying aortic pathology and clinical urgency did not
appear to significantly influence the outcome, according to
our results, despite the expectation that the extent of aortic
dissection may influence the rate of spinal-cord ischaemia
due to varying degrees of interruption of spinal-cord
perfusion [13].
4.2. Operator factors
Individual surgeons have preferences as to how they
implement their clinical practice and are influenced by the
evidence base for specific interventions and their personal
experience and training pathway.
4.3. Hospital factors
Facilities need to be in place to enable a multidisciplinary
approach; hence, ‘hospital factors’ are a further important
consideration. In addition, the cost—benefit ratio and
available budget must be considered because the added
cost of revascularisation surgery is considerable. The mean
hospital stay for patients with and without pre-stenting LSA
revascularisation, where data were available, was 14.9 days
and 10.9 days, respectively. It would be useful to perform a
cost-effectiveness analysis to evaluate this for consideration
in decision making of management of patients with LSA
coverage.
Stent-graft type and availability are also influential. We
expect that the type of stent graft used (fenestrated/
branched) may also affect outcome though the different
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tionmay confound these findings. We excluded graft type as a
distinction from the study because none of the studies
included in the analysis used fenestrated or branched grafts.
This turned out to be beneficial because this has enabled the
focus to be on approved techniques/devices and not of
investigational tools and experimental techniques.
Combining these findings, we emphasise that LSA manage-
ment decision making requires careful considered action.
There are currently no Agency for Healthcare Research and
Quality (AHRQ, USA) or National Institute for Health and
Clinical Excellence (NICE, UK) guidelines available. If LSA
coverage is necessary to create an optimal LZ, then, a
decision needs to be made on whether or not to perform LSA
revascularisation. The decision needs to be made on an
individual basis taking into account patient, operator and
hospital factors in the context of the clinical urgency.
4.4. Strengths and limitations
An important limitation is that the study was not based on
randomised evidence and enabled comparison of only a
limited number of comparative studies in some subgroup
analyses. A randomised controlled trial would be valuable but
would be expensive and impractical. Exclusions also limited
the study to English-only articles.
It is important to be aware of potential statistical and
clinical heterogeneity, which could influence the findings.
Statistical heterogeneity was limited as much as possible
through careful consideration of the inclusion and exclusion
criteria and robust application of the search protocol.
In such a study, clinical heterogeneity can be introduced
because numerous operators (of a presumed varied skill base)
in different centres were included. In addition, there were
confounding factors which we could not account for. We
expect that variation in peri-procedural blood pressure
would affect outcomes such as spinal-cord ischaemia [14].
We presume that variations in haemodynamic parameters,
recording, reporting and blood-pressure management pro-
tocols existed between studies but these data were not
available for extraction. In addition, the length of thoraco-
abdominal aorta covered by a stent graft or the degree of LSA
coverage would be expected to influence the outcome and
this information too was not available. The degree of pre-
existing disease of cerebral and intra-arch vasculature is also
known to affect the stroke rate and this was not factored for
in this study [13].
5. Conclusions
Management of the LSA during TEVAR is complex.
Coverage of the LSA origin may cause downstream ischaemic
complications, which may be overcome by revascularising
the LSA. However, these strategies themselves may worsen
the overall patient outcome. Therefore, taking into con-
sideration the availability of time and facilities, we propose
assessing each individual carefully by taking into account
patient, operator and hospital factors. In this way, a bespoke
approach is necessary to achieve the best risk—benefit ratio
for the individual patient.References
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